This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ADSTILADRIN
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SUO 2024
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Conference Highlights
2023 International Bladder Cancer Network
Viewing 1-18 of 18 articles
IBCN 2023: Proteogenomic Characterization of Chemotherapy Response in Muscle Invasive Bladder Cancer
IBCN 2023: Initial Results From The Prospective Randomized UroFollow Trial Comparing Markerguided vs. Cystoscopy-Based Standard Follow-Up In Patients With Low/Intermediate Risk Bladder Cancer
IBCN 2023: Urinary Comprehensive Genomic Profiling Predicts Urothelial Cancer Up To 12 Years Ahead Of Clinical Diagnosis: An Expanded Analysis Of The Golestan Cohort Study
IBCN 2023: A Composite Biomarker Approach to Spare Neoadjuvant Chemotherapy in Select Muscle-Invasive Bladder Cancer Patients
IBCN 2023: Molecular Signatures Predict GEMDOCE Responses for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
IBCN 2023: Simulating The Effects of Molecular Urine Markers In Follow-Up Of Patients With High Risk Non-Muscle Invasive Bladder Cancer
IBCN 2023: Added Value of ctDNA Testing For Identifying FGFR3 Alterations In Metastatic Urothelial Cancer Eligible For Erdafitinib Treatment
IBCN 2023: Gene Expression-Based Classification of Urothelial Carcinoma For Research And Clinical Applications
IBCN 2023: Alignment Of Molecular Subtypes Across Multiple Bladder Cancer Subtyping Classifiers
IBCN 2023: Meta-Analysis of GWAS Data from Diverse Populations for Bladder Cancer (mapBC) Collaboration: Initial Findings
IBCN 2023: Exploring the Impact of Microbiome in the Response of Combined Radiation with Immune Checkpoint Blockade in Muscle Invasive Bladder Cancer
IBCN 2023: Patient-Derived Organoids Identify Tailored Therapeutic Options and Determinants of Plasticity in Sarcomatoid Urothelial Bladder Cancer
IBCN 2023: Field Cancerization Impacts Tumor Development, T-Cell Exhaustion and Clinical Outcomes in Bladder Cancer
IBCN 2023: Evaluation of Molecular Residual Disease by Urinary Comprehensive Genomic Profiling in the SWOG S1605 Phase II Study of Atezolizumab in Patients with BCG Unresponsive NMIBC
IBCN 2023: An Holistic and Intergrated Approach for Investigating the Bacterial Microbiome, Gene Expression Profile and Immune Cell Profile in the Non-Muscle Invasive Bladder Cancer Tumour Microenvironment
IBCN 2023: SURE-01: Interim Results of a Phase 2 Study of Neoadjuvant Sacituzumab Govitecan, Followed by Radical Cystectomy, for Patients with Muscle-Invasive Bladder Cancer
IBCN 2023: Transurethral Resections of Bladder Tumor Quality Criteria and Early Recurrence Rate: Preliminary Data from the International RESECT Study
IBCN 2023: Long Term Recurrence Risk, Metastatic Potential, and Length of Surveillance of Low Grade Non-Muscle Invasive Bladder Cancer
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free